Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report

por Gonugunta, Amrit S., von Itzstein, Mitchell S., Gerber, David E.
Publicado 2022

Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?

por von Itzstein, Mitchell S., Gerber, David E., Minna, John D.
Publicado 2020

How lung cancer cells change identity

por von Itzstein, Mitchell S, Drapkin, Benjamin J, Minna, John D
Publicado 2021

Circulating mitochondrial DNA as a biomarker for lung cancer screening

por von Itzstein, Mitchell S., Gerber, David E., Minna, John D.
Publicado 2022

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report

por Gerber, David E., Mayer, Melissa, Gagan, Jeffrey, von Itzstein, Mitchell S.
Publicado 2022

Severe destructive nasopharyngeal granulomatosis with polyangiitis with superimposed skull base Pseudomonas aeruginosa osteomyelitis

por von Itzstein, Mitchell S, Abeykoon, Jithma P, Summerfield, Daniel D, Whitaker, Jennifer A
Publicado 2017

Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report

por Edmondson, Shelby, von Itzstein, Mitchell S., Reys, Brian, Mayer, Melissa, Gagan, Jeffrey, Gerber, David E.
Publicado 2022

Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care qualit...

por von Itzstein, Mitchell S., Gupta, Arjun, Kernstine, Kemp H., Mara, Kristin C., Khanna, Sahil, Gerber, David E.
Publicado 2020

Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection

por von Itzstein, Mitchell S., Lu, Rong, Kernstine, Kemp H., Halm, Ethan A., Wang, Shidan, Xie, Yang, Gerber, David E.
Publicado 2020

Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors

por von Itzstein, Mitchell S., Gonugunta, Amrit S., Wang, Yiqing, Sheffield, Thomas, Lu, Rong, Ali, Sadia, Fattah, Farjana J., Xie, Donglu, Cai, Jennifer, Xie, Yang, Gerber, David E.
Publicado 2022

Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors

por von Itzstein, Mitchell S., Gonugunta, Amrit S., Wang, Yiqing, Sheffield, Thomas, Lu, Rong, Ali, Sadia, Fattah, Farjana J., Xie, Donglu, Cai, Jennifer, Xie, Yang, Gerber, David E.
Publicado 2022

T-cell tolerant fraction as a predictor of immune-related adverse events

por Ostmeyer, Jared, Park, Jason Y, von Itzstein, Mitchell S, Hsiehchen, David, Fattah, Farjana, Gwin, Mary, Catalan, Rodrigo, Khan, Shaheen, Raj, Prithvi, Wakeland, Edward K, Xie, Yang, Gerber, David E
Publicado 2023

Association between immune-related adverse event timing and treatment outcomes

por Hsiehchen, David, Naqash, Abdul Rafeh, Espinoza, Magdalena, Von Itzstein, Mitchell S., Cortellini, Alessio, Ricciuti, Biagio, Owen, Dwight H., Laharwal, Mehak, Toi, Yukihiro, Burke, Michael, Xie, Yang, Gerber, David E.
Publicado 2022

Humoral and cellular correlates of a novel immune-related adverse event and its treatment

por Gonugunta, Amrit S, von Itzstein, Mitchell S, Mu-Mosley, Hong, Fattah, Farjana, Farrar, J David, Mobely, Angela, Rashdan, Sawsan, Lai, Sunny, Bhai, Salman F, Bermas, Bonnie L, Karp, David, Li, Quan-Zhen, Wakeland, Edward K, Gerber, David E
Publicado 2021

Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon

por Khan, Shaheen, von Itzstein, Mitchell S., Lu, Rong, Bermas, Bonnie L., Karp, David R., Khan, Saad A., Fattah, Farjana J., Park, Jason Y., Saltarski, Jessica M., Gloria‐McCutchen, Yvonne, Xie, Yang, Li, Quan‐Zhen, Wakeland, Edward K., Gerber, David E.
Publicado 2020

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors

por Mundra, Vatsala, Yang, Yuqiu, von Itzstein, Mitchell S., Fattah, Farjana, Gonugunta, Amrit S., Hannan, Raquibul, Pop, Laurentiu M., Zhang, Yuanyuan, Wang, Yiqing, Sheffield, Thomas, Xie, Yang, Dowell, Jonathan E., Homsi, Jade, Rashdan, Sawsan, Park, Jason, Li, Quan-Zhen, Wakeland, Edward K., Gerber, David E.
Publicado 2023

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors

por Ahmed, Murtaza, von Itzstein, Mitchell S, Sheffield, Thomas, Khan, Shaheen, Fattah, Farjana, Park, Jason Y, Popat, Vinita, Saltarski, Jessica M, Gloria-McCutchen, Yvonne, Hsiehchen, David, Ostmeyer, Jared, Khan, Saad A, Sultana, Nazima, Xie, Yang, Li, Quan-Zhen, Wakeland, Edward K, Gerber, David E
Publicado 2021

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

por von Itzstein, Mitchell S., Gonugunta, Amrit S., Sheffield, Thomas, Homsi, Jade, Dowell, Jonathan E., Koh, Andrew Y., Raj, Prithvi, Fattah, Farjana, Wang, Yiqing, Basava, Vijay S., Khan, Shaheen, Park, Jason Y., Popat, Vinita, Saltarski, Jessica M., Gloria-McCutchen, Yvonne, Hsiehchen, David, Ostmeyer, Jared, Xie, Yang, Li, Quan-Zhen, Wakeland, Edward K., Gerber, David E.
Publicado 2022